Recurrent Respiratory Papillomatosis (Rrp) Treatment With A Dna Vaccine
Posted Date: Dec 22, 2020
- Investigator: Aaron Friedman
- Specialties:
- Type of Study: Device & Drug
Patients with HPV-6 and /or HPV-11 based RRP will be treated with a series of intramuscular injections of a DNA Vaccine and followed for a period of two years to see if their RRP inter-surgical interval increases.
Criteria:
Adult Patients With Pre-Existing Hpv-6 And/Or Hpv-11 Based Rrp Requiring 2 Surgical Procedures Per Year For The 3 Years Prior To Study Entry.
Keywords:
Rrp, Papilloma, Immunotherapy
For More Information:
Aaron Friedman
513-475-8400
friedma5@ucmail.uc.edu